RecruitingNCT01109368

The Rogosin Institute Homozygous Familial Hypercholesterolemia Repository


Sponsor

The Rogosin Institute

Enrollment

60 participants

Start Date

Jun 1, 2010

Study Type

OBSERVATIONAL

Conditions

Summary

This repository will establish for the first time a system to carefully assess and monitor over time the general health and the amount of cholesterol in the arteries of U.S. children and adults with homozygous familial hypercholesterolemia (hoFH). Patients with this very rare disorder have very high blood levels of cholesterol from birth due to the inheritance of an abnormal gene from each parent. As a result, if untreated, heart attacks and sudden death occur in childhood. Treatments such as LDL-apheresis and liver transplant will lower the cholesterol level, but the best treatment and the best way to monitor the effect of the treatment on the arteries are unknown. The collection of clinical data and blood for analysis of known and yet-to-be discovered markers and predictors of arterial disease will yield new information about the natural history of the disorder and response to treatment. The repository will greatly aid the development of specific protocols that seek to learn more about this disease and new therapies.


Eligibility

Plain Language Summary

Simplified for easier understanding

This repository collects clinical and genetic data from patients with Homozygous Familial Hypercholesterolemia (hoFH) — an extremely rare inherited condition that causes dangerously high LDL ("bad") cholesterol levels from birth, often leading to heart disease at a very young age. The repository supports research into new treatment options for this life-threatening condition. You may be eligible if: - You are any age - You have documented untreated LDL cholesterol above 500 mg/dL with normal triglycerides, PLUS at least one of the following: - A confirmed genetic mutation in the LDL receptor or ApoB gene - Both biological parents have LDL above 160 mg/dL - A parent or grandparent had coronary artery disease at a young age - You developed tendon/skin xanthomas before age 10 or heart disease before age 20 You may NOT be eligible if: - You (or your parent, if you are under 18) are unable to sign informed consent Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.


Locations(1)

Weill Cornell Medical College

New York, New York, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT01109368


Related Trials